Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Early screening and administration of DKD are beneficial for renal outcomes of type 2 diabetic patients. However, the current early diagnosis using the albuminuria/creatine ratio (ACR) contains limitations. This study aimed to compare serum lipidome variation between type 2 diabetes and early DKD patients with increased albuminuria through an untargeted lipidomics method to explore the potential lipid biomarkers for DKD identification. 92 type 2 diabetic patients were enrolled and divided into two groups: DM group (ACR < 3 mg/mmol, = 49) and early DKD group (3 mg/mmol ≤ ACR < 30 mg/mmol, = 43). Fasting serum was analyzed through an ultraperformance liquid mass spectrometry tandem chromatography system (LC-MS). Orthogonal partial least-squares discriminant analysis (OPLS-DA) and univariate and multivariate analysis were performed to filter differentially depressed lipids. Receiver operating characteristic (ROC) curves were used to estimate the diagnostic capability of potential lipid biomarkers. We found that serum phospholipids including phosphatidylserine (PS), sphingomyelin (SM), and phosphatidylcholine (PC) were significantly upregulated in the DKD group and were highly correlated with the ACR. In addition, a panel of two phospholipids including PS(27:0)-H and PS(30:2e)-H showed good performance to help clinical lipids in early DKD identification, which increased the area under the curve (AUC) from 0.568 to 0.954. The study exhibited the serum lipidome variation in early DKD patients, and the increased phospholipids might participate in the development of albuminuria. The panel of PS(27:0)-H and PS(30:2e)-H could be a potential biomarker for DKD diagnosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552467PMC
http://dx.doi.org/10.1021/acsomega.3c05504DOI Listing

Publication Analysis

Top Keywords

early dkd
16
type diabetic
12
serum phospholipids
8
dkd
8
diabetic patients
8
serum lipidome
8
lipidome variation
8
dkd patients
8
patients increased
8
potential lipid
8

Similar Publications

Aims: To investigate the association between Flow-Mediated Dilation (FMD) and the urinary albumin-to-creatinine ratio (UACR) in individuals with type 2 diabetes mellitus (T2DM).

Methods: This cross-sectional study involved 194 individuals diagnosed with T2DM. Participants were categorized into two groups based on their UACR levels: the diabetic kidney disease group (DKD) (UACR≥30 mg/g) and the non-diabetic kidney disease group (non-DKD) (UACR <30 mg/g).

View Article and Find Full Text PDF

Kidney transcriptomics signature of prospective rapid diabetic kidney disease progression.

BMC Nephrol

August 2025

Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Background: Previous cross-sectional transcriptomics studies on diabetic kidney disease (DKD) kidney tissue have shown correlations between gene expression and both disease status and kidney function at the time of biopsy; however, longitudinal data are scarce.

Methods: We utilized clinical follow-up data up to five years post-biopsy, linking the transcriptomes of diagnostic kidney biopsies to progression rates and outcomes in 19 patients with DKD. Patients were stratified into “rapid progressors” and “non-rapid progressors” based on clinical parameters (eGFR slope, CKD stage advancement, degree of albuminuria, composite outcome of kidney failure or 40% eGFR decline).

View Article and Find Full Text PDF

Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.

Pharmaceuticals (Basel)

July 2025

Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, 90127 Palermo, Italy.

Chronic Kidney Disease (CKD) is a major global health issue, with diabetes being its primary cause and cardiovascular disease contributing significantly to patient mortality. Recently, two classes of medications-sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)-have shown promise in protecting both kidney and heart health beyond their effects on blood sugar control. We conducted a narrative review summarizing the findings of different clinical trials and mechanistic studies evaluating the effect of SGLT2i and GLP-1 RAs on kidney function, cardiovascular outcomes, and overall disease progression in patients with CKD and DKD.

View Article and Find Full Text PDF

Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (), affecting 20%-50% of patients and leading to end-stage kidney disease (ESKD). This review synthesizes literature on CKD in , focusing on the epidemiology, pathophysiology, and management strategies, including oral hypo-glycemic agents and emerging therapies. A systematic search across PubMed, Scopus, and Web of Science prioritized studies from 2010 to 2025.

View Article and Find Full Text PDF

Background: Tubulointerstitial lesions (TILs) play a crucial role in the progression of diabetic kidney disease (DKD). Current clinical prediction methods rely heavily on invasive biopsies and fall short of providing a comprehensive, multidimensional assessment.

Methods: This multicenter study, conducted from 2010 to 2024, involved patients with biopsy-confirmed DKD.

View Article and Find Full Text PDF